The Complexity Behind the Acronym
Antibody-drug conjugates (ADCs) are a class of targeted oncology therapeutics that combine the selectivity of a monoclonal antibody with the potency of a cytotoxic small molecule payload. The concept is elegant: deliver a chemotherapy agent directly to the tumour cell, spare normal tissue, and improve the therapeutic index over conventional chemotherapy. The execution is considerably more demanding.
The next generation of conjugated therapeutics, often grouped under the XDC umbrella, extends the conjugation concept beyond antibodies to include peptides, nanobodies, small molecules, and even oligonucleotides as targeting vehicles. Each variation introduces new chemistry, new stability considerations, and new analytical challenges. For a CDMO to credibly support an ADC or XDC programme, it needs capabilities that span formulation science, high-potency manufacturing, linker and conjugation chemistry, and a bioanalytical function capable of characterising every component of the molecule.
The End-to-End Requirements of an ADC Development Programme
| Development Stage | Key Activity | Technical Requirement | Ardena Capability |
| Drug substance development | API synthesis and characterisation of cytotoxic payload | HPAPI synthesis or handling at OEB 4-5; analytical characterisation of warhead | Pamplona: HPAPI containment; analytical characterisation |
| Linker-payload synthesis | Assembly of linker-payload intermediate or final conjugate | Controlled synthesis of reactive intermediates; high-sensitivity analytical monitoring | Specialist chemistry capability; MS-based characterisation |
| Formulation development | Stabilisation of the ADC in solution or lyophilised form | Buffer optimisation; excipient compatibility; physical stability of the antibody-drug conjugate | Ghent: injectable and lyophilisation formulation expertise |
| Analytical characterisation | DAR determination, aggregation, charge variant analysis | HIC, SEC-HPLC, icIEF, LC-MS for intact mass and peptide mapping | Assen: analytical platform for complex biologic characterisation |
| GMP manufacturing | Aseptic fill-finish of the final conjugated product | Sterile manufacturing with HPAPI handling capability | Ghent: aseptic fill-finish; HPAPI containment |
| Bioanalysis | PK characterisation of total antibody, conjugated antibody, free payload, and ADA | LBA and LC-MS/MS validated methods; ICH M10 compliance | Assen: integrated ADC bioanalytical programme |
The Linker Is Not Just a Chemical Spacer
A common misconception in early ADC development is that the linker is a simple chemical bridge between the antibody and the payload, and that its design is secondary to the choice of antibody and warhead. In reality, the linker determines where and when the payload is released, how stable the conjugate is in systemic circulation, and how quickly it degrades after uptake into the tumour cell.
Cleavable linkers, which release the payload in response to conditions found in the tumour microenvironment such as low pH, elevated protease activity, or reductive conditions, offer the advantage of targeted payload release but must be stable enough in circulation to avoid premature release and off-target toxicity. Non-cleavable linkers, which release the payload only after complete lysosomal degradation of the antibody, are more stable in circulation but release a metabolite of the payload rather than the payload itself, which may have different potency and pharmacokinetic properties.
The FDA’s guidance on ADC development addresses the characterisation requirements for the linker-payload component and the stability testing needed to demonstrate adequate linker stability under physiologically relevant conditions.
HPAPI Handling: The Non-Negotiable Safety Requirement
The cytotoxic payloads used in ADCs are among the most potent compounds handled in pharmaceutical manufacturing. Maytansinoids, auristatins, calicheamicins, and pyrrolobenzodiazepines are typically active at picomolar concentrations and have occupational exposure limits in the nanogram per cubic metre range. Manufacturing with these payloads requires engineering controls, closed systems, and operator monitoring programmes that go well beyond standard pharmaceutical handling practices.
Occupational exposure banding (OEB) is the framework used to classify the hazard of a compound and define the engineering controls required for its manufacture. Most ADC payloads fall into OEB 4 or OEB 5, requiring isolator or dedicated closed-system manufacturing environments. Ardena’s Pamplona facility provides OEB 4 and 5 containment capability for HPAPI handling, offering the safety infrastructure needed for ADC payload work without the need to build or operate dedicated in-house HPAPI facilities.
Why ADC Programmes Need an Integrated Partner
The multi-component nature of an ADC programme is precisely why integration matters. The formulation decisions made for the drug product affect the linker stability, which affects the bioanalytical characterisation required, which affects the PK data interpretation, which informs the dose selection for Phase I. When each of these activities sits with a different vendor, data flows between organisations with inevitable delays and potential for misinterpretation.Ardena’s ability to handle HPAPI synthesis at Pamplona, aseptic fill-finish and lyophilisation at Ghent, and bioanalytical characterisation at Assen within a single project management framework gives ADC programmes the integration that their complexity requires.
